PET Imaging

Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that enables visualization of metabolic processes in the body. The basics of PET imaging is that the technique detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (also called radiopharmaceuticals, radionuclides or radiotracer). The tracer is injected into a vein on a biologically active molecule, usually a sugar that is used for cellular energy. PET systems have sensitive detector panels to capture gamma ray emissions from inside the body and use software to plot to triangulate the source of the emissions, creating 3-D computed tomography images of the tracer concentrations within the body.

The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate cancer, providing a more effective imaging approach to detect the spread of cancer to other parts of the body. Piflufolastat F-18 injection is the first fluorinated prostate-specific membrane antigen (PSMA) agent approved by the FDA and also the first commercially available PSMA PET imaging agent.
News | PET Imaging
FDA Approves First Commercially Available PSMA PET Imaging Agent for Prostate Cancer

June 28, 2021 — The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate ...

Time June 28, 2021
arrow
GE Healthcare also recently announced Xeleris V, a new virtualized, flexible AI-powered solution that provides clinicians secure access to data from anywhere – helping them make personalized care decisions and treatment recommendations that are at the heart of precision health.
News | Nuclear Imaging
GE Healthcare Advances Precision Health & Theranostics With New Products & Solutions

June 22, 2021 — At the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2021 summer conference, GE Healthcare ...

Time June 22, 2021
arrow
A phase III clinical trial has validated the effectiveness of the prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL in detecting and localizing recurrent prostate cancer.
News | Prostate Cancer
PSMA-Targeted Radiotracer Pinpoints Metastatic Prostate Cancer Across Anatomic Regions

June 21, 2021 — A phase III clinical trial has validated the effectiveness of the prostate-specific membrane antigen ...

Time June 21, 2021
arrow
A novel positron emission tomography (PET) radiotracer has been shown to effectively measure increases in brain tau—a distinguishing characteristic of Alzheimer’s disease—before any symptoms of the disease are observed.
News | PET Imaging
New PET Tracer Detects Hallmark of Alzheimer’s Disease Years Before Symptoms Emerge

June 16, 2021 — A novel positron emission tomography (PET) radiotracer has been shown to effectively measure increases ...

Time June 16, 2021
arrow
SNMMI's Image of the Year is a detailed depiction of areas of cognitive impairment, neurological symptoms and comparison of impairment over a six-month time frame
News | PET Imaging
SNMMI Image of the Year: PET Imaging Measures Cognitive Impairment in COVID-19 Patients

June 16, 2021 — The effects of COVID-19 on the brain can be accurately measured with positron emission tomography (PET) ...

Time June 16, 2021
arrow
A new imaging technique has the potential to detect neurological disorders — such as Alzheimer's disease — at their earliest stages, enabling physicians to diagnose and treat patients more quickly. Termed super-resolution, the imaging methodology combines position emission tomography (PET) with an external motion tracking device to create highly detailed images of the brain.
News | PET Imaging
New Super-resolution Technique Allows for More Detailed Brain Imaging

June 14, 2021 — A new imaging technique has the potential to detect neurological disorders — such as Alzheimer's disease ...

Time June 14, 2021
arrow
Positron emission tomography (PET) using a 68Ga-labeled fibroblast activation protein inhibitor (FAPI) can noninvasively identify and monitor pulmonary fibrosis, according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting.
News | PET-CT
Radiotracer Effective for Detection and Assessment of Lung Fibrosis

June 14, 2021 — Positron emission tomography (PET) using a 68Ga-labeled fibroblast activation protein inhibitor (FAPI) ...

Time June 14, 2021
arrow
News | PET-CT
Canon Medical’s Digital PET/CT System Receives FDA Clearance

June 10, 2021 — Bringing the power of artificial intelligence (AI) to molecular imaging, Advanced intelligent Clear-IQ ...

Time June 10, 2021
arrow
The U.S. Food and Drug Administration (#FDA) approved #Aduhelm (#aducanumab) for the treatment of #Alzheimer’s, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments.
News | PET Imaging
FDA Grants Accelerated Approval for Alzheimer’s Drug Aduhelm

June 7, 2021 — The U.S. Food and Drug Administration (FDA) approved Aduhelm (aducanumab) for the treatment of Alzheimer ...

Time June 07, 2021
arrow
Winship Cancer Institute of Emory University’s EMPIRE-1 trial is first-of-its-kind randomized patient outcomes study of amino acid PET imaging in influencing a cancer control endpoint
News | Radiation Therapy
Results Published for Axumin (Fluciclovine F 18) PET Imaging Study Demonstrating Improved Patient Outcomes in Patients with Recurrent Prostate Cancer

May 25, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 25, 2021
arrow
According to an open-access article in ARRS’ American Journal of Roentgenology (AJR), increased axillary lymph node or ipsilateral deltoid uptake is occasionally observed on FDG or 11C-choline PET performed after Pfizer-BioNTech or Moderna COVID-19 vaccination
News | Coronavirus (COVID-19)
Nodal and Deltoid Radiotracer Uptake on Post-COVID-19 Vaccination PET

May 19, 2021 — According to an open-access article in ARRS’ American Journal of Roentgenology (AJR), increased axillary ...

Time May 19, 2021
arrow
Videos | Coronavirus (COVID-19)
VIDEO: COVID Vaccine Adenopathy Can Last Up to 10 Weeks

Yael Eshet, M.D., MSc, a diagnostic radiology specialist at Sheba Medical Center in Israel, was the lead author on a ...

Time May 11, 2021
arrow
GE Healthcare announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology biomarkers that help enable more personalized healthcare. The company aims to develop and bring to market Zionexa’s pipeline biomarkers, as well as the recently FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18)
News | PET Imaging
GE Healthcare Acquires Zionexa

May 6, 2021 — GE Healthcare announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology ...

Time May 06, 2021
arrow
After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by
News | PET Imaging
PET Imaging Adds Valuable Information to Brain Metastasis Monitoring

May 5, 2021 — For patients with brain metastases, amino acid positron emission tomography (PET) can provide valuable ...

Time May 05, 2021
arrow
olecular Targeting Technologies, Inc. (MTTI) announced the issuance of United States Patent # 10,953,113. The patent claims a quick (5 min), easy and quantitative conversion of commercially available 18F-deoxyglucose (18F-FDG) to 18F-Fluroglucaric acid (18F-FGA).
News | PET Imaging
Molecular Targeting Technologies, Inc. Announces New PET Imaging Agent

April 19, 2021 — Molecular Targeting Technologies, Inc. (MTTI) announced the issuance of United States Patent # 10,953 ...

Time April 19, 2021
arrow
The inflamed joints of a #rheumatoid #arthritis patient are clearly visible in the #PET images with the novel 68Ga-DOTA-Siglec-9 #radiopharmaceutical. Image courtesy of Anne Roivainen
News | PET Imaging
Promising Results from First-in-humans Study of a Novel PET Radiopharmaceutical

April 19, 2021 — The preliminary trial results of a novel radiopharmaceutical for PET imaging of inflammation developed ...

Time April 19, 2021
arrow
News | PET-CT
PET/CT Shows Stressed Brain Linked to Broken Heart

March 29, 2021 — Heightened activity in the brain, caused by stressful events, is linked to the risk of developing a ...

Time March 29, 2021
arrow
Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the Biograph Vision Quadra, a positron emission tomography/computed tomography (PET/CT) scanner designed for clinical use as well as translational research – or the application of scientific research to create therapies and procedures that improve health outcomes. In this manner, the Biograph Vision Quadra expands precision medicine.
News | PET-CT
Siemens Healthineers Announces FDA Clearance of Biograph Vision Quadra Extended Axial FoV PET/CT Scanner

March 8, 2021 — Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the Biograph ...

Time March 08, 2021
arrow
Axial fused PET/CT image shows intense uptake (arrowhead) in the deep pelvis corresponding to the left lobe of the prostate in a 62-year-old with a history of prostate cancer treated with radiation therapy. The CT scan does not show the tumor. Image courtesy of the the Radiological Society of North America.
Feature | Treatment Planning | By Melinda Taschetta-Millane
Using PET to Enhance Prostate Treatment Planning

The decision to offer radiation after prostatectomy for patients with recurrent prostate cancer is quite complex, and ...

Time March 05, 2021
arrow
Findings indicate that PPC and GG are highly predictive of overall upstaging by PSMA PET/CT for patients with high-risk prostate cancer
News | PET-CT
Model Helps Predict Which Patients will Benefit Most from PSMA PET Scan

February 23, 2021 — A new study led by researchers at the UCLA Jonsson Comprehensive Cancer Center helps identify which ...

Time February 23, 2021
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now